Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape

Emily N. Kinsey, Tian Zhang, Andrew J. Armstrong

Research output: Contribution to journalReview articlepeer-review

17 Scopus citations


Purpose In recent years, the treatment options for metastatic hormone-sensitive prostate cancer (mHSPC) have expanded significantly. In addition to androgen deprivation therapy, the systemic treatments now include docetaxel, abiraterone, enzalutamide, and apalutamide. Radiation to the primary is also an option for select low-volume patients. Methods We conducted a review of the pivotal trials that have changed the practice of mHSPC. Results We describe an overview of the trials that investigated docetaxel (CHAARTED and STAMPEDE-Docetaxel), abiraterone (LATTITUDE and STAMPEDE-Abiraterone), enzalutamide (ARCHES, ENZAMET), apalutamide (TITAN), and radiation to the primary (STAMPEDE-Radiation). Discussion The treatment of mHSPC is a complex topic, and treatment choice should be individualized. Patient preferences, cost, volume of disease, and side effect profiles are important in determining which option is the best for an individual patient.

Original languageEnglish (US)
Pages (from-to)64-75
Number of pages12
JournalCancer Journal
Issue number1
StatePublished - Jan 1 2020
Externally publishedYes


  • Abiraterone
  • apalutamide
  • docetaxel
  • enzalutamide
  • hormone-sensitive prostate cancer

ASJC Scopus subject areas

  • Oncology
  • Cancer Research


Dive into the research topics of 'Metastatic Hormone-Sensitive Prostate Cancer: A Review of the Current Treatment Landscape'. Together they form a unique fingerprint.

Cite this